Those patients are from the aviptadil expanded access study. They were very, very ill, too ill to qualify for the clinical trial. That's why the mortality rate was so high and shouldn't be seen as indicative as to what happened during their clinical trial.

It may be germane to our trial because we included severe patients excluded in the aviptadil trial, they excluded those on ECMO, but we'll obviously just have to wait to see the makeup of our trial as far as the amount of very sick patients included and how it affected overall mortality.